The C1s antibody prepared by the True North Therapeutics, Inc prevents the destruction of human red blood cells exposed to plasma samples of patients with a type of autoimmune hemolytic anemia. The article entitled "TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinin disease patient autoantibodies" was published on-line in the journal Blood earlier this month. TNT003 is the murine analog of True North's lead humanized monoclonal antibody drug candidate, TNT009, for which the company plans to initiate the first clinical program in 2015.
In ex vivo studies using plasma samples from patients with a type of AIHA known as cold agglutinin disease (CAD), True North demonstrated that red blood cells exposed to patient samples contained high levels of Complement proteins deposited on the cell surface. True North showed that by inhibiting Complement deposition on the red blood cell membrane, TNT003 prevented the red blood cells from being engulfed by macrophages, immune cells responsible for clearing Complement-coated cells and debris from the blood. TNT003 also prevented direct red blood cell lysis driven by a CAD sample that contained unusually high levels of autoantibodies, suggesting that a Complement inhibitor like TNT003 could be efficacious in severe cases of CAD.
TNT003 inhibits C1s, a member of the Complement family of plasma proteins, which, upon activation, trigger a powerful enzymatic cascade that destroys and removes pathogens from the circulation. However, aberrant Complement system activation has been described in numerous autoimmune settings in which antibodies that attack self, known as autoantibodies, play a role in disease pathogenesis. Like other forms of AIHA, CAD is a disorder in which anti-red blood cell antibodies bind to and lead to the destruction of patient red blood cells through Complement system activation.
Dr. Panicker further stated, "As Complement system activity is the only known driver of red blood cell destruction in patients with CAD, the results in the study published in Blood provide compelling evidence for the development of TNT009, the company's lead humanized monoclonal antibody, for the treatment of CAD and potentially other forms of AIHA, for which no approved therapies exist."